Interventions
Start with what is being proposed—then ask what was shown.
This map organizes intervention coverage around concepts readers recognize. Availability, development stage, mechanism, evidence, safety, and meaningful outcomes remain separate judgments.
Five reader-facing groups
A category is a starting point, not a verdict.
Future records will make development stage obvious—available today, off-label, human trials, preclinical, theoretical, or unknown—without treating progress as proof of benefit.
Lifestyle, nutrition, and prevention
Exercise, nutrition and dietary patterns, fasting and caloric restriction, sleep and circadian health, and preventive medicine.
Evidence question: Was the intervention tested against a comparison, for long enough, in a relevant population, using a meaningful outcome?
Coverage not yet publishedApproved, off-label, and experimental candidates
Future coverage may include mTOR inhibitors, metformin, senolytics, NAD-related compounds, GLP-1 drugs, and other candidates only when source-backed reporting exists.
Evidence question: What indication, population, dose, outcome, development stage, and safety context were actually studied?
Coverage not yet publishedProducts with distinct evidence and quality questions
Supplements remain separate from pharmaceuticals because regulation, label accuracy, product quality, dosing, and evidence require different scrutiny.
Evidence question: Is the evidence about an ingredient, a specific formulation, a biomarker, or a meaningful health outcome?
Coverage not yet publishedGene, RNA, cell, and regenerative approaches
Partial reprogramming, gene and RNA therapies, stem and immune cells, tissue regeneration, plasma factors, organ replacement, and bioprinting.
Evidence question: Was the work performed in cells, animals, or humans, and what efficacy, durability, delivery, control, and safety gaps remain?
Coverage not yet publishedClocks, biomarkers, wearables, imaging, and diagnostics
Measurement tools can describe a signal without showing that changing the signal improves function, healthspan, or lifespan.
Evidence question: Is the measurement reliable, validated, actionable, and connected to an outcome that matters?
Coverage not yet publishedHow future pages will read
One intervention, several independent judgments.
- Stage
- Availability and development progress—not efficacy.
- Mechanism
- What researchers think it affects—not automatically what it achieves.
- Evidence
- Outcome- and population-specific support, limitations, conflicts, and uncertainty.
- Safety
- Known risks, unknowns, regulatory context, and tradeoffs kept visible.
Continue exploring